TheraVet: Increasingly Successful Attendance in Major Ortho EU & US Conferences and North America Launch of BIOCERA-VET COMBO-CLEAN
October 18 2023 - 1:30AM
Business Wire
- Commercial success at the ESVOT congress and ACVS conference
with an ever-growing number of vets visiting TheraVet’s
booths
- BIOCERA-VET use for surgical management of canine
osteosarcoma highlighted in a poster session
- Launch of BIOCERA-VET COMBO-CLEAN, a unique antibiotic
long-lasting releasing bone substitute, in North America
Regulatory News:
TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering
company in the management of osteoarticular diseases in pets,
continues its efforts on the deployment of its commercial
strategy in attending major conferences dedicated to veterinary
surgeons in Europe and United-States.
The Company attended the annual congress of the European Society
of Veterinary Orthopaedics and Traumatology (ESVOT) (5-7 October,
Venice, Italy) organized under a new format to address a specific
topic in-depth and gathered nearly 350 participants. This
year focus on “Complication in Traumatology” was addressing
topics of interest to BIOCERA-VET such as the full session
dedicated to the management of bone infection where the use of
local antibiotherapy was debated. Furthermore, BIOCERA-VET was
also highlighted in a poster dedicated to osteosarcoma
management: “In situ minimally invasive calcium phosphate
cement injection for conservative surgical management of
appendicular osteosarcoma in typical and atypical locations in dogs
“. Finally, the Company strong commercial presence allowed to meet
with ~20% of the participants.
After Europe, then Company participated to the ACVS surgery
Summit, organized from October 12 to 14 (Louisville, USA) by the
prestigious American College of Veterinary Surgery. The ACVS
represent the largest event dedicated to veterinary surgery in USA
with more than 1500 participants (from USA and abroad) and about
150 exhibitors with all the important players in orthopaedic
surgery represented. The Company strong commercial presence allowed
to meet with ~10% of the participants.
After Europe in May 2023, the Company takes advantage of this
important event to officially launch BIOCERA-VET®
Combo-Clean, the new reference of BIOCERA-VET® product line,
in North America (USA and Canada). BIOCERA-VET®
Combo-Clean is available on a dedicated website
(www.bioceravet.com). BIOCERA-VET® Combo-Clean is the
first-of-its-kind sustained antibiotic releasing bone substitute
allowing the local of management bone infection while supporting
bone healing and mechanical strength. Proof of the interest shown
in this new reference, the first sales were recorded during the
ACVS conference.
About TheraVet SA TheraVet is a veterinary biotechnology
company specializing in osteoarticular treatments for companion
animals. The Company develops targeted, safe and effective
treatments to improve the quality of life of pets suffering from
joint and bone diseases. For pet owners, the health of their pets
is a major concern and TheraVet’s mission is to address the need
for innovative and curative treatments. TheraVet works closely with
international opinion leaders in order to provide a more effective
response to ever-growing needs in the field of veterinary medicine.
TheraVet is listed on Euronext Growth® Paris and Brussels, has its
head office in Belgium (Gosselies) with a US subsidiary. For more
information, visit the TheraVet website or follow us on LinkedIn /
Facebook / Twitter
About BIOCERA-VET In close collaboration with an
international scientific board, THERAVET® has developed a new line
of calcium-phosphate and biological bone substitutes, BIOCERA-VET®.
BIOCERA-VET® is a full range of innovative, easy-to-use, efficient
& cost-effective bone substitutes indicated in bone surgeries
where a bone graft is required and as a palliative alternative in
the management of canine osteosarcoma. Based on extremely promising
clinical results, this line offers the possibility of a better,
more convenient and more efficient orthopedic surgery. BIOCERA-VET®
is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, a ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
- BIOCERA-VET® COMBO-CLEAN, a local and long-lasting antibiotic
delivery calcium-phosphate bone substitute
For more information, visit BIOCERA-VET website.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231017518816/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
NewCap Investor Relations and Financial Communications
Théo Martin / Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44
71 94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@thera.vet Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Sep 2024 to Oct 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Oct 2023 to Oct 2024